245554-93-2

Upstream product

• 63-91-2 L-phenylalanine 
• 1493-27-2 ortho-nitrofluorobenzene 
• 615-36-1 2-bromoaniline 
• 952060-26-3 N-(2-nitrophenyl)-phenylalanine 
• 6613-41-8 ethyl 3-phenylpyruvate 
• 95-54-5 1,2-diamino-benzene 
• 1132769-58-4 (2S)-2-(2-nitrophenylamino)-3-phenylpropionic acid methyl ester 

Downstream Products

• 1132769-71-1 C₂₃H₂₀N₂O₃ 
• 1261061-27-1 C₂₆H₃₂N₂O₃ 

Relevant academic research and scientific papers

Iron- or Zinc-Mediated Synthetic Approach to Enantiopure Dihydroquinoxalinones

A general and efficient synthesis of enantiopure dihydroquinoxalinones has been developed using naturally occurring amino acids as starting materials. The reductive cyclization of N-(o-nitroaryl)amino esters was performed by using iron and zinc metal under mild conditions in a water/ethyl acetate mixture. The corresponding dihydroquinoxalinones were obtained in moderate to high yields and high enantiomeric purity, among which 7 new compounds were unprecedented in the literature.

Metal-free tandem cyclization/hydrosilylation to construct tetrahydroquinoxalines

A one-pot tandem procedure involving cyclization and sequential hydrosilylation of imines and amides under the catalysis of B(C6F5)3 has been developed for the step-economical construction of 1,2,3,4-tetrahydroquinoxalines directly from readily available 1,2-diaminobenzenes, α-ketoesters and low-cost, safe polymethylhydrosiloxane (PMHS). This metal-free approach provides various products in good to excellent yields, and displays a wide range of substrate scope and a high degree of functional group tolerance even to reduction-sensitive moieties. The choice of hydrosilanes is critical to the catalysis, and PMHS has proved to be optimal. Decreasing the amount of PMHS could enable the reaction to stop at the 3,4-dihydroquinoxalin-2(1H)-one stage. The procedure is convenient and scalable, and neither a dried solvent nor an inert atmosphere is required. Moreover, the enantioselective construction of these products was explored, and promising results were achieved.

Efficient synthesis of useful heterocycles via transition metal-catalyzed cascade processes

This paper reports our recent results from synthesis of some useful heterocycles, for example oxazolidinones, indoles, and quinoxalinones, by transition metal-catalyzed cascade processes. The scope and limitations of these procedures and the reaction mech

A general and practical access to chiral quinoxalinones with low copper-catalyst loading

A general, straightforward, and practical access to multi-substituted chiral quinoxalin-2-ones has been achieved based on the copper(I) chloride-dimethylethylenediamine (DMEDA) catalyst system. With the use of 1 mol% copper(I) chloride, structurally diverse quinoxalin-2-ones were generated with high optical purity from readily available starting materials, 2-haloanilines and α-amino acids, in a one-pot manner.

Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors

In an effort to identify HDAC isoform selective inhibitors, we designed and synthesized novel, chiral 3,4-dihydroquinoxalin-2(1H)-one and piperazine-2,5-dione aryl hydroxamates showing selectivity (up to 40-fold) for human HDAC6 over other class I/IIa HDACs. The observed selectivity and potency (IC50 values 10-200 nM against HDAC6) is markedly dependent on the absolute configuration of the chiral moiety, and suggests new possibilities for use of chiral compounds in selective HDAC isoform inhibition.

INHIBITORS OF HISTONE DEACETYLASE

This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I); wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.

Quinoxalinones as serine protease inhibitors such as factor XA and thrombin

This invention discloses quinoxalinones which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts and prodrugs of the compounds, pharmaceutically acceptable compositions comprising the compounds, their salts or prodrugs, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.